Pharmacokinetics and pharmacodynamics of terbutaline in healthy horses

American Journal of Veterinary Research

Volumn 61, Issue 7, 2000, Pages 761-765

  Törneke, M Karolina ^a   Ingvast Larsson, J Carina ^a   Johansson, Jenny M ^a   Appelgren, Lars Erik ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TERBUTALINE;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; HEART RATE; HYPERVENTILATION; LACTATE BLOOD LEVEL; LETHARGY; NONHUMAN; TACHYCARDIA; TOXICITY TESTING;

ANIMALIA; EQUIDAE;

EID: 0343192438     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.761     Document Type: Article

References (18)

1. Rang HP, Dale MM, Ritter JM. Pharmacology. 3rd ed. New York: Laurence Hunter, 1995;358-359.
2. Murphy JR, McPherson EA, Dixon PM. Chronic obstructive pulmonary disease (COPD): effects of bronchodilating drugs on normal and affected horses. Equine Vet J 1980;12:10-14.
3. Hansson E, Nyberg JA, Ohlsson B. Effekten av intramuskulärt injicerat terbutalin på häst. Svensk Veterinärtidning 1985;37:477-480.
4. Plumb DC. Veterinary drug handbook. 3rd ed. Ames, Iowa: Iowa State University Press, 1999;689-690.
5. Törneke K, Ingvast Larsson C, Appelgren LE. A comparison between clenbuterol, salbutamol and terbutaline in relation to receptor binding and in vitro relaxation of equine tracheal muscle. J Vet Pharmacol Ther 1998;21:388-392.
6. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In: Swarbrick J, ed. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc. 1982;409-417.
7. Davies DS. Pharmacokinetics of terbutaline after oral administration. Eur J Respir Dis 1484;134(suppl):111-117.
8. Tegner K, Nilsson HT, Persson CGA, et al. Elimination pathways of terbutaline. Eur J Respir Dis 1984;134(suppl):93-100.
9. Nyberg L. Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis 1984;134(suppl): 149-160.
10. Leferink JG, van den Berg W, Wagemaker-Engels I, et al. Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. Arzneimittelforschung 1982;32:159-164.
11. Hochhaus G, Mollmann H. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol 1992;30:342-362.
12. Törneke K. β-Adrenoceptors in equine trachea and heart. Vet Res Commun 1999;23:41-51.
13. Gordeladze JO, Jynge I, Borchgrevink PC, et al. Enhanced responsiveness of the myocardial beta-adrenoceptor-adenylate cyclase system in the perfused rat heart (I). Biosci Rep 1998;18: 229-250.
14. Cotton DB, Strassner HT, Lipson LG, et al. The effects of terbutaline on acid base, serum electrolytes, and glucose homeostasis during the management of preterm labor. Am J Obstet Gynecol 1981;141:617-624.
15. Persson SGB. Heart rate and blood lactate responses to submaximal treadmill exercise in the normally performing Standardbred trotter - age and sex variations and predictability from the total red blood cell volume. Zentralbl Veterinarmed A 1997;44:125-132.
16. Sasse HL, Hajer R. NAB 365, a beta 2-receptor sympathomimetic agent: clinical experience in horses with lung disease. J Vet Pharmacol Ther 1978:1:241-244.
17. Kallings P, Ingvast-Larsson C, Persson SGB, et al. Clenbuterol plasma concentrations alter repeated oral administration and its effects on cardio-respiratory and blood lactate responses to exercise in healthy Standardbred horses. J Vet Pharmacol Ther 1991;14:243-249.
18. Erichsen DF, Aviad AD, Schultz RH, et al. Clinical efficacy and safety of clenbuterol HCl when administered to effect in horses with chronic obstructive pulmonary disease. Equine Vet J 1994;26:331-336.